Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression

Gene Therapy

Volumn 12, Issue 11, 2005, Pages 911-917

  Pipiya, T ^a   Sauthoff, H ^a,b   Huang, Y Q ^a   Chang, B ^a   Cheng, J ^a   Heitner, S ^a   Chen, S ^a   Rom, W N ^a   Hay, J G ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Hypoxia; Translation

Indexed keywords

ADENOVIRUS VECTOR; CELL PROTEIN; E1A PROTEIN; MESSENGER RNA; VIRUS PROTEIN;

AMBIENT AIR; ARTICLE; CANCER CELL; CANCER THERAPY; CELL CYCLE S PHASE; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HYPOXIA; LUNG CANCER; NONHUMAN; NORTHERN BLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; BLOTTING, NORTHERN; CELL HYPOXIA; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; RNA, MESSENGER; RNA, VIRAL; S PHASE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VIRAL PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA;

EID: 20744460916     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302459     Document Type: Article

References (32)

1. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-851.
2. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002; 3: 17-26.
3. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002; 13: 3-13.
4. Harrison D et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 2001; 12: 1323-1332.
5. Doronin K et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147-6155.
6. Sauthoff H et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003; 14: 425-433.
7. Roelvink PW et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909-7915.
8. Kim M et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38: 1917-1926.
9. Rauen KA et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002; 62: 3812-3818.
10. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276.
11. 2? Adv Exp Med Biol 1997; 411: 209-214.
12. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-447.
13. Wouters BG et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38: 240-257.
14. Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem 2004; 385: 223-230.
15. Horwitz MS. Adenoviridae and their replication. In: Fields BN, Knipe DM (eds). Virology. Lippincott Williams & Wilkins: New York, 2001, pp 2301-2326.
16. Goda N et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23: 359-369.
17. Gardner LB et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 2001; 276: 7919-7926.
18. Gardner LB, Li F, Yang X, Dang CV. Anoxic fibroblasts activate a replication checkpoint that is bypassed by E1a. Mol Cell Biol 2003; 23: 9032-9045.
19. Goodrum ED, Ornelles DA. Roles for the E4 orf6, orf3, and E1B 55-kiloDalton proteins in cell cycle-independent adenovirus replication. J Virol 1999; 73: 7474-7488.
20. Goodrum FD, Ornelles DA. The early region 1B 55-kiloDalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol 1997; 71: 548-561.
21. Kraggerud SM, Sandvik JA, Pettersen EO. Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res 1995; 15: 683-686.
22. Koumenis C et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 2002; 22: 7405-7416.
23. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278: 29655-29660.
24. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
25. Curiel DT, Gerritsen WR, Krul MR. Progress in cancer gene therapy. Cancer Gene Ther 2000; 7: 1197-1199.
26. Howe JA et al. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci USA 1990; 87: 5883-5887.
27. Schneider RJ, Mohr I. Translation initiation and viral tricks. Trends Biochem Sci 2003; 28: 130-136.
28. Cuesta R, Xi Q, Schneider RJ. Structural basis for competitive inhibition of eIF4G-Mnk1 interaction by the adenovirus 100-kiloDalton protein. J Virol 2004; 78: 7707-7716.
29. Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus Res 1995; 39: 75-82.
30. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
31. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
32. Sauthoff H, Heitner S, Rom WN, Hay JG. Deletion of the adenoviral E1b-19 kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379-388.